Table 3.
Competing risk regression analysis for the predictors of mortality among young adults aged 20–24 years old living with HIV
| Unadjusted | Adjusted | |||
|---|---|---|---|---|
| Variable | HR (95% CI) | p‐value | aHR (95% CI) | p‐value |
| Sex | ||||
| Female | 1.0 | 1.0 | ||
| Male | 2.0 (1.3–2.8) | 0.002 | 1.4 (0.9–2.2) | 0.108 |
| BMI | ||||
| BMI <18.5 (underweight) | 1.0 | 1.0 | ||
| 18.5 ≤ BMI < 24 (normal) | 2.4 (1.6–3.7) | < 0.001 | 2.1 (1.3–3.3) | 0.001 |
| 24 ≤ BMI < 27 (overweight) | 0.4 (0.2–0.9) | 0.036 | 0.5 (0.2–0.9) | 0.044 |
| BMI ≥ 27 (obese) | 0.8 (0.3–1.8) | 0.548 | 0.8 (0.4–2.1) | 0.721 |
| CD4 count (cells/mm3) | ||||
| > 500 | 1.0 | 1.0 | ||
| 350–500 | 1.9 (0.6–2.3) | 0.597 | 1.1 (0.6–2.1) | 0.719 |
| 200–349 | 1.5 (0.8–3.0) | 0.235 | 1.4 (0.7–2.8) | 0.326 |
| < 200 | 3.2 (2.0–5.2) | < 0.001 | 2.8 (1.7–4.5) | < 0.001 |
| WHO Stage | ||||
| WHO Stage I | 1.0 | |||
| WHO Stage II | 4.1 (2.6–6.4) | < 0.001 | ||
| WHO Stage III | 8.0 (5.3–12.2) | < 0.001 | ||
| WHO Stage IV | 30 (15.5–59.9) | < 0.001 | ||
| Regimen combination | ||||
| EFV based | 1.0 | 1.0 | ||
| DTG based | 1.8 (0.8–4.1) | 0.164 | 1.7 (0.7–3.9) | 0.208 |
| NVP based | 8.3 (3.6–19.1) | < 0.001 | 8.2 (3.5–19.6) | < 0.001 |
| TB co‐infection | ||||
| No | 1.0 | 0.208 | ||
| Yes | 2.4 (0.6–9.8) | |||
| Facility type | ||||
| Public | 1.0 | |||
| Private | 0.9 (0.6–1.4) | 0.801 | ||
Note: Global p‐value <0.001. Adjusted for sex, BMI, CD4 and regimen combination at enrolment.
Abbreviations: aSHR, adjusted subhazard ratio; BMI, body mass index; CI, confidence interval; DTG, dolutegravir; EFV, efavirenz; NVP, nevirapine; PI, protease inhibitor; SHR, subhazard ratio; TB, tuberculosis; WHO, World Health Organization.